Lucid Diagnostics is a commercial-stage medical technology enterprise focused on preventing cancer through the early detection of precancerous conditions. Its operations center on commercializing proprietary non-invasive diagnostic tests—specifically the EsoCheck cell collection device paired with the EsoGuard EsoCheck DNA assay—designed to identify esophageal precancer and prevent deaths from esophageal adenocarcinoma in patients suffering from chronic gastroesophageal reflux disease.